Specified Drug-Use Survey on Vedolizumab for IV Infusion 300 mg [Crohn's Disease]
Not Applicable
Recruiting
- Conditions
- Crohn's disease
- Registration Number
- JPRN-jRCT1080224753
- Lead Sponsor
- Takeda Pharmaceutical Company Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- recruiting
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
1. Have moderate or severe active CD
2. Have inadequate response to existing therapies
Exclusion Criteria
1. Patients with any contraindication for vedolizumab
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method